#USA #New York #Atossa Therapeutics #Z-Endoxifen #Dr. Steven Quay

Atossa Therapeutics CEO to Present at H.C. Wainwright Conference

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on innovative breast cancer treatments, is set to showcase its advancements at the 27th Annual H.C. Wainwright Global Investment Conference. The event will take place on September 8, 2025, at the distinguished Lotte New York Palace Hotel. Dr. Steven Quay, Atossa's Chairman and CEO, will engage in a fireside chat with Emily Bodnar, a biotech research analyst at H.C. Wainwright.

In this discussion, Dr. Quay will provide crucial insights into Atossa's lead program, (Z)-endoxifen, a promising Selective Estrogen Receptor Modulator (SERM). This compound is designed to provide a dual-action approach aimed at both treating and preventing breast cancer, potentially revolutionizing current treatment protocols. Recent feedback from regulatory advisors has been encouraging, indicating possible acceleration in the company’s development path.

The conference will offer a platform for investors to understand Atossa's ongoing projects, especially in relation to (Z)-endoxifen, which is undergoing various clinical studies. Dr. Quay’s presentation will include updates on the clinical trials and the encouraging developments that have emerged recently, emphasizing their strategic direction and commitments to innovation in the biotechnology field.

Additionally, the session will be broadcast live, and a replay will be accessible for about 90 days on the company's investor relations website. Those interested in a sneak peek of the presentation can view a 60-second video message from Dr. Quay, which highlights Atossa’s vision and the momentum building around its future.

Atossa Therapeutics aims to transform the landscape of breast cancer management. By targeting the disease at both treatment and preventative stages, the company is positioned uniquely in the biopharma arena. With (Z)-endoxifen as their flagship candidate, Atossa is also pursuing various pioneering techniques that could expand therapeutic options for women, something that is particularly relevant in today’s healthcare environment.

Investors looking to engage with Atossa’s management can schedule meetings through the conference portal or reach out directly via a company representative. This engagement is seen as critical for strengthening relationships with stakeholders and providing a clearer picture of their developmental strategy moving forward.

Atossa Therapeutics stands firm in its mission to disrupt conventional treatment paradigms through rigorous research and cutting-edge science, aiming not only to develop effective therapies but also to ensure comprehensive patient care. For more information about Atossa, interested parties can visit their official website and explore the company’s commitment to advancing breast cancer therapeutics and the significant milestones on the horizon.

Conclusion

As the company prepares for this key investment conference, the anticipation surrounding Dr. Quay’s presentation reflects a broader optimism for innovative biomedical developments. Atossa Therapeutics continues to be one of the companies to watch in the biopharmaceutical landscape, paving the way for enhanced breast cancer treatment options for women worldwide.